<span item_type="fundamental" item_id="c5bc1c9fe503cba717a4e0b1a0da65c9" counter_id="ST/US/SRTA" env="prod"></span><span item_type="announcement" item_id="581211382865597057" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 49.3 M, beating the estimate of USD 43.75 M.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.12.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -6.749 M.</p><p></p><h3>Financial Metrics by Segment</h3><h4>Segment Revenue</h4><ul><li>Total revenue increased 36.7% to $49.3 million in Q3 2025 versus $36.1 million in the prior year period. Excluding Keystone, revenue increased 29.0% versus the prior year period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1779128/000162828025050785/srta-earningreleasexq32025.htm"></span></li></ul><h4>Operational Metrics</h4><ul><li>Net loss from continuing operations increased by $4.0 million versus the prior year to - $9.7 million, driven primarily by a $5.2 million increase in realized loss from sales of short-term investments and a legal reserve in the current period, which was partially offset by a $4.1 million increase in Adjusted EBITDA.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1779128/000162828025050785/srta-earningreleasexq32025.htm"></span></li><li>Adjusted EBITDA increased by $4.1 million year-over-year to $4.2 million in the current quarter versus $0.1 million in the prior year period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1779128/000162828025050785/srta-earningreleasexq32025.htm"></span></li><li>Medical Segment Adjusted EBITDA increased by $3.6 million to $7.6 million versus the prior year period. Medical Segment Adjusted EBITDA margin rose to 15.3% in Q3 2025 versus 10.8% in Q3 2024 driven by revenue growth and the increase in Flight Margin.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1779128/000162828025050785/srta-earningreleasexq32025.htm"></span></li><li>Total operating expenses increased 27.3% to $54.9 million in Q3 2025 versus $43.2 million in Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1779128/000162828025050785/srta-earningreleasexq32025.htm"></span></li><li>Gross profit increased 75.9% to $9.5 million in Q3 2025 versus $5.4 million in Q3 2024. Gross margin improved to 19.4% in Q3 2025 from 15.0% in Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1779128/000162828025050785/srta-earningreleasexq32025.htm"></span></li><li>Flight Profit increased 54.7% to $11.6 million in Q3 2025 versus $7.5 million in Q3 2024. Flight Margin improved to 23.6% in Q3 2025 from 20.8% in Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1779128/000162828025050785/srta-earningreleasexq32025.htm"></span></li></ul><h4>Cash Flow</h4><ul><li>Operating Cash Flow was - $37.3 million in Q3 2025, driven by $44.3 million of Keystone acquisition consideration that was directed by the seller to be paid through payroll post-close to employees participating in a “phantom equity” plan and therefore was required to be included in operating cash flow under accounting rules which more than offset other operating cash flow.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1779128/000162828025050785/srta-earningreleasexq32025.htm"></span></li><li>Free Cash Flow from continuing operations was $1.9 million in Q3 2025 and excludes acquisition consideration, transaction costs related to the sale of the Passenger business and operating cash flow from discontinued operations. Free Cash Flow from continuing operations, before aircraft and engine acquisitions was $2.7 million in Q3 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1779128/000162828025050785/srta-earningreleasexq32025.htm"></span></li></ul><h4>Balance Sheet</h4><ul><li>Ended Q3 2025 with $75.9 million in cash and short-term investments.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1779128/000162828025050785/srta-earningreleasexq32025.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Raised 2025 revenue guidance to $185-195 million, reaffirmed Adjusted EBITDA range.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1779128/000162828025050785/srta-earningreleasexq32025.htm"></span></li><li>Investor Day scheduled for November 17th 2025; will introduce 2026 guidance and medium-term financial targets.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1779128/000162828025050785/srta-earningreleasexq32025.htm"></span></li></ul>

Strata Critical Medical | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 49.3 M